March 12, 2019—Nikon Instruments will debut the OS-15-N, a digital slide scanning system featuring Nikon optics, at the USCAP annual meeting, March 16–21, National Harbor, Md. Nikon partnered with OptraScan to provide an end-to-end digital pathology solution that uses Nikon’s optics and OptraScan’s desktop slide scanning system, the OS-15. The OS-15-N features Nikon’s highest level, research-grade Plan Apo Lambda objectives, which combine the company’s Nano Crystal Coat technology and high numerical aperture. With Plan Apo correction, “true image reproduction with minimal distortion is guaranteed, enabling edge-to-edge quantitation and maximum data throughput and reproducibility,” the company reports. The OS-15-N system also includes OptraScan’s ImagePath for web-based image management and viewing and TelePath cloud-based telepathology solution for real-time digital conferencing.
Webinars and Sponsored Roundtables — Register Now
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, July 21, 2026, 11:00-11:30 AM CT
- Explain how transparency and manufacturer partnerships improve quality, consistency, and decision-making confidence in specimen management.
- Evaluate blood collection tubes beyond cost and commodity assumptions, incorporating clinical impact and risk into decision-making.
- Assess the potential risk points when using a blood collection device that has not been cleared for a specific purpose.
Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY